Online inquiry

IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8609MR)

This product GTTS-WQ8609MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8609MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9731MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ8323MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ13700MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ9346MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ13782MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ2547MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ12623MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ9508MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA J2898A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW